U.S., March 27 -- ClinicalTrials.gov registry received information related to the study (NCT06896110) titled 'Phase 1 Trial of Intrathecal Azacitidine and Nivolumab in Patients with Recurrent High-grade Glioma' on March 19.
Brief Summary: This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Glioblastoma (GBM)
Diffuse Midline Glioma (DMG)
Astrocytoma, IDH-Mutant, Grade 4
Diffuse Hemispheric Glioma, H3 G34-Mutant
Gliosarcoma of Brain
Intervention:
DRUG: Nivolumab
Intrathecal nivolumab will be given at a flat dose of 40 mg
...